Renalytix Plc - ADR Stock

$0.18

2.86%

Nasdaq, Fri, Jul 25 2025

ISIN

US75973T1016

Symbol

RNLX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Technology

Overview Dividends Analysts Charts Strategies

Renalytix Plc - ADR Stock price

$0.18

-15.31 98.84% 5Y

Nasdaq, Closing price Fri, Jul 25 2025

+0.01 2.86%

ISIN

US75973T1016

Symbol

RNLX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Technology

Key metrics

Basic

Market capitalization

$32.3m

Enterprise Value

Net debt

Cash

Shares outstanding

Valuation (TTM | estimate)

P/E

negative | negative

P/S

13.6 | 3.1

EV/Sales

- | -

EV/FCF

P/B

Financial Health

Equity Ratio

-126.6%

Return on Equity

506.1%

ROCE

ROIC

Debt/Equity

Financials (TTM | estimate)

Revenue

$2.4m | $10.3m

EBITDA

$-29.1m | $-16.5m

EBIT

$-30.3m | $-18.7m

Net Income

$-34.8m | -

Free Cash Flow

$-22.8m

Growth (TTM | estimate)

Revenue

-1.7% | 349.9%

EBITDA

20.0% | 42.2%

EBIT

22.1% | 38.8%

Net Income

18.8% | -

Free Cash Flow

35.4%

EPS

$-0.2

FCF per Share

Short interest

1.5%

Employees

102

Rev per Employee

$20.0k

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

Renalytix Plc - ADR Stock Analysis

Unlock Scores for Free

??

5 Analysts have issued a Renalytix Plc - ADR forecast:

4x Buy

80%

1x Hold

20%

More details on Analyst Estimates Including Price Targets

5 Analysts have issued a Renalytix Plc - ADR forecast:

Buy

80%

Hold

20%

Analyst Estimates with Stock Price Targets

Financial data from Renalytix Plc - ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	2.37 2.37	2% 2% 100%
- Direct Costs	1.88 1.88	16% 16% 79%
Gross Profit	0.50 0.50	213% 213% 21%
- Selling and Administrative Expenses	20 20	48% 48% 859%
- Research and Development Expense	- -	- -
EBITDA	-29 -29	20% 20% -1,229%
- Depreciation and Amortization	1.21 1.21	52% 52% 51%
EBIT (Operating Income) EBIT	-30 -30	22% 22% -1,280%
Net Profit	-35 -35	19% 19% -1,468%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Company Profile

Renalytix Plc manufactures medical devices and equipment. It offers artificial intelligence for kidney disease. The company was founded by James McCullough on March 15, 2018 and is headquartered in Penarth, the United Kingdom.

Head office	United Kingdom
CEO	James McCullough
Employees	102
Founded	2018
Website	renalytix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now